US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

2.20

-0.0899-3.93%

Post-market: 2.17-0.0301-1.37%19:39 EDT

Volume:156.72K

Turnover:346.74K

Market Cap:8.94M

PE:8.31

High:2.45

Open:2.11

Low:2.01

Close:2.29

Loading ...

Overview Company News Filings

Neo-Concept International Grp Hldngs Ltd trading halted, news pending

Neo-Concept International Approves 5-to-1 Share Consolidation Effective June 16, 2025

Press Release: Shell Plc First Quarter 2025 Euro and GBP Equivalent Dividend Payments

Nasdaq Applies to SEC to Add XRP, SOL, ADA, XLM to Cryptocurrency Index

Scotiabank reports second quarter results

Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025

Shell announces commencement of a share buyback programme

Press Release: Shell plc First Quarter 2025 Interim Dividend

Shell plc publishes first quarter 2025 press release

DMC Global Reports First Quarter Financial Results

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

ORYZON Raises €30 Million in Capital Increase

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Preliminary results for the year ended 31 December 2024

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

ACCESS Newswire

Shell first quarter 2025 update note

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NCI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":2.2001,"timestamp":1750708800000,"preClose":2.29,"halted":0,"volume":156722,"hourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.2001,"latestTime":"19:39 EDT","volume":5248,"amount":11326.2926,"timestamp":1750721995163},"delay":0,"floatShares":945200,"shares":4064000,"eps":0.264765,"marketStatus":"Closed","change":-0.0899,"latestTime":"06-23 16:00:00 EDT","open":2.11,"high":2.45,"low":2.01,"amount":346735.74921100005,"amplitude":0.19214,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.264765,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750752000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":2.29,"dividendRate":0.000455,"preHourTrading":{"tag":"盘前","latestPrice":2.1,"preClose":2.29,"latestTime":"09:29 EDT","volume":14099,"amount":29275.789595600003,"timestamp":1750685369862},"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.2001,"latestTime":"19:39 EDT","volume":5248,"amount":11326.2926,"timestamp":1750721995163},"volumeRatio":0.295532},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":945200,"roa":"6.39%","roe":"29.62%","lyrEps":0.264765,"volumeRatio":0.295532,"shares":4064000,"dividePrice":0.001,"high":2.45,"amplitude":0.19214,"preClose":2.29,"low":2.01,"week52Low":1.4,"pbRate":"1.24","psRate":"0.30","week52High":9,"institutionHeld":0.7857,"latestPrice":2.2001,"eps":0.264765,"divideRate":0.000455,"volume":156722,"delay":0,"ttmEps":0.264765,"open":2.11,"prevYearClose":3.3,"prevWeekClose":2.29,"prevMonthClose":1.948,"prevQuarterClose":2.4,"fiveDayClose":1.703,"twentyDayClose":1.78,"sixtyDayClose":2.1005},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543687656","title":"Neo-Concept International Grp Hldngs Ltd trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2543687656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543687656?lang=en_us&edition=fundamental","pubTime":"2025-06-14 07:50","pubTimestamp":1749858613,"startTime":"0","endTime":"0","summary":"19:50 EDT Neo-Concept (NCI) International Grp Hldngs Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neo-concept-international-grp-hldngs-ltd-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neo-concept-international-grp-hldngs-ltd-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2542199875","title":"Neo-Concept International Approves 5-to-1 Share Consolidation Effective June 16, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542199875","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542199875?lang=en_us&edition=fundamental","pubTime":"2025-06-12 20:00","pubTimestamp":1749729625,"startTime":"0","endTime":"0","summary":"HONG KONG, June 12, 2025 - Neo-Concept International Group Holdings Ltd. has announced a share consolidation approved at their Extraordinary General Meeting on May 9, 2025. This consolidation will merge every five issued and unissued shares into one share, altering the authorized share capital structure. Effective June 16, 2025, the Class A Ordinary Shares will continue trading under the symbol \"NCI\" with a new CUSIP Number, G6421C120, on the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neo-Concept International Group Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire  on June 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL7lgrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","LU2210149790.SGD","BK4202","IE00BKPKM429.USD","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NDAQ","BK4585","NCI","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2542877555","title":"Press Release: Shell Plc First Quarter 2025 Euro and GBP Equivalent Dividend Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2542877555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542877555?lang=en_us&edition=fundamental","pubTime":"2025-06-09 14:00","pubTimestamp":1749448800,"startTime":"0","endTime":"0","summary":"SHELL PLC FIRST QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS. The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the first quarter 2025 interim dividend, which was announced on May 2, 2025 at US$0.358 per ordinary share.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling, at the pound sterling rate per ordinary share shown above.Euro and pounds sterling dividends payable in cash have been converted from US dollars based on an average of market exchange rates over the three dealing days from June 4 to June 6, 2025. This dividend will be payable on June 23, 2025 to those members whose names were on the Regi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU0300736062.USD","NCI","BK4202","LU2236285917.USD","BK4588","SHEL","BK4585","LU0098860793.USD","LU0278409577.USD","BK4201","LU0300736492.USD","LU1162221912.USD"],"gpt_icon":0},{"id":"2542785838","title":"Nasdaq Applies to SEC to Add XRP, SOL, ADA, XLM to Cryptocurrency Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2542785838","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542785838?lang=en_us&edition=fundamental","pubTime":"2025-06-09 09:22","pubTimestamp":1749432120,"startTime":"0","endTime":"0","summary":"BlockBeats News, June 9th, according to Cryptotimes, on June 7th, Nasdaq filed a rule change proposal with the U.S. Securities and Exchange Commission , planning to include XRP, Solana , Cardano , and Stellar Lumens  in its crypto index benchmark. This adjustment involves the Hashdex Nasdaq Crypto Index ETF , aiming to expand its tracking assets from the original Nasdaq Crypto US Settlement Price Index  to cover 9 tokens in the Nasdaq Crypto Index .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/297435","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK1184","MNQmain","BK7105","01336","BK4129","TSYW.SI","SOL.USD.HKCC","NQmain","NCI","ADA.AU","SQQQ","PSQ","TQQQ","APT.USD.HKCC","AVAX.USD.HKCC","NCIQ","BK7083","BK4519","QLD","SOL","SEC.AU","USJW.SI","USAW.SI","BK1584","FDN","SOL.AU",".IXIC","QID","BK1550","TON.USD.CC","TON.USD.HKCC","NVIW.SI","BK7016","APT.USD.CC","BK4202"],"gpt_icon":1},{"id":"2539402736","title":"Scotiabank reports second quarter results","url":"https://stock-news.laohu8.com/highlight/detail?id=2539402736","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539402736?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:00","pubTimestamp":1748340000,"startTime":"0","endTime":"0","summary":"Second Quarter 2025 Highlights on a Reported Basis . Net income of $2,032 million, compared to $2,092 million         Earnings per share  of $1.48, compared to $1.57  Return on equity of 10.1%, compared to 11.2%. Net income of $2,072 million, compared to $2,105 million  Earnings per share  of $1.52, compared to $1.58  Return on equity of 10.4%, compared to 11.3%. TORONTO, May 27, 2025 /CNW/ - The Bank of Nova Scotia    reported second quarter net income of $2,032million compared to $2,092million in the same period last year. Diluted earnings per share  were $1.48, compared to $1.57 in the same period a year ago.Adjusted net income for the second quarter was $2,072 million and adjusted diluted EPS were $1.52, down from $1.58 last year. Adjusted return on equity was 10.4% compared to 11.3% a year ago.International Banking generated adjusted earnings of $719 million, up 7% year-over-year, with solid revenue generation and lower provision for credit losses, reflecting improvements in the p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scotiabank-reports-second-quarter-results-100000297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","USA","BK4202","BK4207","BNS"],"gpt_icon":0},{"id":"2535567726","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535567726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535567726?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:01","pubTimestamp":1747134060,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include:. -- In January 2025, the Company announced it had closed a $2.5 million. registered direct offering priced at the market under Nasdaq rules.-- Also in January 2025, we announced that we received positive regulatory. guidance from the European Medicines Agency  for the ibezapolstat.  Phase 3 clinical trial program, which is aligned with FDA on. matters of manufacturing, non-clinical and clinical aspects of the Phase. 3 program. The EMA guidance also confirmed ibezapolstat's regulatory. pathway for a Marketing Authorization Application to be filed by the. Company after successful completion ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","MET","LU0310800965.SGD","LU0048573561.USD","BK4194","LU1989772840.SGD","BK4022","LU1267930227.SGD","BK4202","LU0128525689.USD","LU1571399168.USD","LU0251142724.SGD","LU1496350502.SGD","BK4588","BK4162","BK4131","VRE","BK4232","NCI","BK4139","LU1291159041.SGD","LU0251131958.USD","LU0742534661.SGD","BK4585","BK4563","R","BK4533","BK4539","FDX","LU0052756011.USD","LU1989772923.USD","GAIN","BK4135","ACXP"],"gpt_icon":0},{"id":"2534224579","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2534224579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534224579?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:00","pubTimestamp":1747051200,"startTime":"0","endTime":"0","summary":"-- Successful completion of EUR30 Million capital increase, with strong. -- Awarded non-refundable EU grant of EUR13.26 Million through the first. Important Project of Common European Interest  in the health. -- Vafidemstat's Phase III PORTICO-2 trial endpoints for agitation and. aggression in BPD defined with input from new Clinical Advisory Board;-- Results of observational clinical study on Phelan-McDermid syndrome. Dr. Buesa continued \"We are finalizing preparations for the upcoming Phase III of vafidemstat for the treatment of agitation and aggression in Borderline Personality Disorder . In collaboration with our recently formed Clinical Advisory Board, comprising leading U.S. psychiatry experts, we have designed a Phase III clinical trial protocol that we believe aligns with FDA expectations. As a continuation of our End-of-Phase 2  dialogue with the FDA, we have received additional requests for complementary information, which we are currently addressing. We expect to submit bot","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2532898794","title":"Shell announces commencement of a share buyback programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2532898794","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532898794?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:03","pubTimestamp":1746165780,"startTime":"0","endTime":"0","summary":"Shell plc  today announces the commencement of a $3.5 billion share buyback programme covering an aggregate contract term of approximately three months . The purpose of the programme is to reduce the issued share capital of the Company. All shares repurchased as part of the programme will be cancelled. It is intended that, subject to market conditions, the programme will be completed prior to the Company’s Q2 2025 results announcement, scheduled for July 31, 2025.The maximum number of ordinary shares which may be purchased or committed to be purchased by the Company under the programme  is 320,000,000, which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at the Company's 2024 Annual General Meeting.The broker will make its trading decisions in relation to the Company's securities independently of the Company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-announces-commencement-share-buyback-060300272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0278409577.USD","BK4156","LU0098860793.USD","LU0300736062.USD","SHEL","LU2236285917.USD","LU0300736492.USD","LU1162221912.USD","BK4588","BK4202","LU0320765646.SGD","BK4201","NCI","BK4585"],"gpt_icon":0},{"id":"2532671288","title":"Press Release: Shell plc First Quarter 2025 Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2532671288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532671288?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:02","pubTimestamp":1746165720,"startTime":"0","endTime":"0","summary":"London, May 2, 2025 - The Board of Shell plc   today announced an interim dividend in respect of the first quarter of 2025 of US$ 0.358 per ordinary share.Details relating to the first quarter 2025 interim dividend. Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling.An alternative 'Electronic Election Entitlement'  process is available in CREST for dividends with options elections.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt  certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the first quarter 2025 interim dividend. The followi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","LU0300736492.USD","NCI","BK4201","SHEL","LU0320765646.SGD","LU1162221912.USD","BK4585","LU0278409577.USD","BK4202","BK4588","LU0300736062.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2532898797","title":"Shell plc publishes first quarter 2025 press release","url":"https://stock-news.laohu8.com/highlight/detail?id=2532898797","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532898797?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:01","pubTimestamp":1746165660,"startTime":"0","endTime":"0","summary":"\"Shell delivered another solid set of results in the first quarter of 2025. We further strengthened our leading LNG business by completing the acquisition of Pavilion Energy, and high-graded our portfolio with the completion of the Nigeria onshore and the Singapore Energy and Chemicals Park divestments.Our strong performance and resilient balance sheet give us the confidence to commence another $3.5 billion of buybacks for the next three months, consistent with the strategic direction we set out at our Capital Markets Day in March.\". Q1 2025 Adjusted Earnings1 of $5.6 billion reflect strong performance across the business. CFFO excluding working capital was $11.9 billion for the quarter. Working capital outflow was $2.7 billion in Q1 2025.Strengthened LNG trading and optimisation capabilities with the Pavilion Energy acquisition and high-graded the portfolio with the completion of the divestments of the Singapore Energy and Chemicals Park2, and SPDC3 in Nigeria.Disciplined capital allo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-publishes-first-quarter-060100623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0300736062.USD","LU0278409577.USD","LU0320765646.SGD","LU0098860793.USD","NCI","LU0300736492.USD","BK4201","BK4585","BK4561","LU2236285917.USD","BK4006","SHEL","LU1162221912.USD","MT","BK4202","BK4588"],"gpt_icon":0},{"id":"2532388020","title":"DMC Global Reports First Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532388020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532388020?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:05","pubTimestamp":1746129900,"startTime":"0","endTime":"0","summary":"First quarter sales were $159.3 million, up 5% sequentially and down 5% versus Q1 2024. Sales at Arcadia, DMC’s architectural building products business, were $65.6 million, up 9% sequentially and up 6% versus last year’s first quarter. The growth reflects higher sales of commercial exterior store front products and interior framing systems, which more than offset an expected decline in high-end residential window and door sales. Arcadia has recently refocused on its core commercial operations while making cost control a priority in the current volatile macroeconomic environment. Adjusted EBITDA attributable to DMC was $5.6 million, up 149% sequentially and up 58% versus the prior-year first quarter.At DynaEnergetics, DMC’s energy products business, first quarter sales were $65.6 million, up 3% sequentially and down 16% versus the year-ago first quarter. The year-over-year decline principally reflects pricing adjustments and lower unit sales associated with weakness in the highly volat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dmc-global-reports-first-quarter-200500938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","NCI","BOOM","BK4179"],"gpt_icon":0},{"id":"2529128986","title":"NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD","url":"https://stock-news.laohu8.com/highlight/detail?id=2529128986","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529128986?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:01","pubTimestamp":1745496060,"startTime":"0","endTime":"0","summary":"Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing. The study was conducted by investigators at Case Western Reserve University  and University Hospitals  and enrolled patients without GERD symptoms who otherwise met AGA recommendations for BE screening. EsoGuard demonstrated excellent negative predictive value  of 100% for detecting esophageal precancer, consistent with its unprecedented precancer detection reported across multiple peer-reviewed clinical validity studies in patients with symptomatic GERD. The study also showed a BE prevalence of 8.4%, a rate comparable to the established prevalence in patients with symptomatic GERD. The manuscript, entitled Nonendoscopic Detection of Barrett's Esophagus in Patients Without GERD Symptoms, is currently available on the leading health sciences preprint server, MedRxiv, and has been submitted for peer-reviewed publication.About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nci-sponsored-study-shows-positive-120100152.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nci-sponsored-study-shows-positive-120100152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DNA","BK4099","BK4202","BK4551","NCI","LCID","BK4555","BK4109","PAVM","PAVMZ","LUCD","NPV","BK4596"],"gpt_icon":0},{"id":"2529986144","title":"ORYZON Raises €30 Million in Capital Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986144","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986144?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"Priced at 2.35 per share, representing a 15.44% discount on the 5-day VWAP. Strong investor demand, with the offering significantly oversubscribed. 15 million anchored by a leading US institutional investor. Proceeds to fund clinical development and corporate initiatives. Maxim , All-Invest , and Singular Bank  acted as bookrunners. Banco Sabadell, S.A. acted as the Settlement and Technical Pre-financing Agent for the Capital Increase, while Gómez-Acebo & Pombo Abogados, S.L.P.  and Gibson, Dunn & Crutcher LLP  served as legal advisors to the Company, and Loeb & Loeb LLP acted as U.S. legal counsel to Maxim Group LLC.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-raises-30-million-capital-120000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1989772923.USD","LU0314104364.USD","IE00BKVL7J92.USD","LU2111349929.HKD","NCI","BK4613","LU2286300806.USD","BK4585","LU0158827781.USD","LU1162221912.USD","LU1074936037.SGD","BK4560","BK4588","BK4554","LU0320765646.SGD","BK4156","LU1548497426.USD","BK4516","NET","LU0795875086.SGD","LU1668664300.SGD","BK4534","LU0106831901.USD","BK4202","LU2023251221.USD","ORYZF","LU0225283273.USD","LU0971096721.USD","BK4504","BK4127","LU0006306889.USD","LU0158827948.USD","LU1989772840.SGD","LU1363072403.SGD","BK4581","LU2133065610.SGD","LU2357305700.SGD","LU1720051017.SGD","LU1732800096.USD","BK4116","BK4548","LU1732799900.SGD","LU2089284900.SGD","LU2271345857.HKD","LU2028103732.USD","LU1720051108.HKD","LU0795875169.SGD","BK4607"],"gpt_icon":0},{"id":"2529569508","title":"Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin","url":"https://stock-news.laohu8.com/highlight/detail?id=2529569508","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529569508?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, April 23, 2025  -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that results from two clinical studies of the Bcl-2 selective inhibitor lisaftoclax  and the MDM2-p53 inhibitor alrizomadlin , two key drug candidates in the company’s apoptosis-targeted pipeline, have been selected for presentations at the 2025 American Society of Clinical Oncology  Annual Meeting. These presentations will include an oral report featuring updated results from a Phase Ib/II study of a lisaftoclax combination regimen in patients with myeloid malignancies.The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community, bringing togethe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascentage-pharma-present-data-two-230000349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","AAPG","BK4139","NCI"],"gpt_icon":0},{"id":"2527413733","title":"ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413733","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413733?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Study conducted under the CRADA agreement between NCI and Oryzon. MADRID and CAMBRIDGE, Mass., April 15, 2025  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibitors  in first line small cell lung cancer  patients with extensive disease, sponsored by the National Cancer Institute , part of the National Institutes of Health. This is the first clinical trial testing the combination of iadademstat with ICI.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-announces-first-patient-dosed-120000598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2286300806.USD","SSI","NCI","BK4560","BK4613","BK4588","BK4585","BK4607","ORYZF","BK4202","BK4548","BK4139","NET","BK4156","BK4116","BK4554"],"gpt_icon":0},{"id":"2527163224","title":"Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2527163224","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527163224?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:30","pubTimestamp":1744716600,"startTime":"0","endTime":"0","summary":"New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ. Finally, RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. Further details can be found here; the Company will provide additional data and explanation following the meeting.About Leptomeningeal Metastases LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid  and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-presents-data-highlighting-113000997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CNS","BK4139","BK4007","CSF","BK4202","LENZ","NCI","PSTV"],"gpt_icon":0},{"id":"2526498953","title":"Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2526498953","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526498953?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:30","pubTimestamp":1744230600,"startTime":"0","endTime":"0","summary":"Amezalpat  is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma ; global investigator support in place. Awarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC. Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis ; data expected 2026. The company has not set a timetable for completion of the process for evaluating strategic alternatives and does not intend to disclose further developments or guidance on the status of its programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary. No agreement providing for any transaction has been reached and there can be no assurances that any transaction will result from the process for evaluating strategic alternatives. If the process for evaluating strategic alterna","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempest-announces-plan-explore-strategic-203000016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","TPST","BK4139","BK4202","OS","HCC","BK4006","BK4097"],"gpt_icon":0},{"id":"2526352564","title":"Preliminary results for the year ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352564?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to 128.8 million compared to 2023, organic r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058256/0/en/Preliminary-results-for-the-year-ended-31-December-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESGR","AGM","CET","NCI","CDMO","CFO","BK4019","BK4159","BK4202","BK4229","BK4195","CAGR","BK4139"],"gpt_icon":0},{"id":"2525092892","title":"Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2525092892","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525092892?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"Gelclair is the company's third commercialized prescription product. Oral mucositis, also called \"chemo mouth,\" a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force. Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients. \"Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs,\" said Conte. \"Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer. We look forward to driving awareness among the oncology nursing community at ONS about Gelclair. Oral mucositis, also called \"chemo mouth,\" is among the most common, painful, and debilitating cancer treatment-related side effects, and it is undertreated and underappreciated. We believe we can hel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/napo-pharmaceuticals-jaguar-health-family-123000734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JAGX","BK4202","BK4007","NCI"],"gpt_icon":0},{"id":"2525063796","title":"Shell first quarter 2025 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2525063796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525063796?lang=en_us&edition=fundamental","pubTime":"2025-04-07 14:00","pubTimestamp":1744005600,"startTime":"0","endTime":"0","summary":"The following is an update to the first quarter 2025 outlook and gives an overview of our current expectations for the first quarter. Outlooks presented may vary from the actual first quarter 2025 res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056424/0/en/Shell-first-quarter-2025-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MT","NCI","BK4202","BK4561","BK4006"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-16","symbol":"NCI","defaultRemindTime":1750080600000,"type":"split","dateTimestamp":1750046400000,"forFactor":5,"toFactor":1,"ratio":5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-06-20","current":10.670242,"percent":0.475862,"low":-615.963293,"twenty":6.311489,"median":14.824233,"eighty":23.64022,"high":50.092968,"avg":7.754804,"sd":47.501563,"marketCap":10960400},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":25.951993,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":14650720},{"date":"2024-06-07","current":26.211896,"twenty":-81.702314,"median":25.015338,"eighty":34.642796,"marketCap":14813280},{"date":"2024-06-14","current":29.519581,"twenty":-78.809845,"median":25.103888,"eighty":32.998302,"marketCap":16682720},{"date":"2024-06-21","current":25.962557,"twenty":-75.44284,"median":25.889128,"eighty":31.491027,"marketCap":14685264},{"date":"2024-06-28","current":22.645555,"twenty":-74.134092,"median":25.192438,"eighty":30.05782,"marketCap":12803632},{"date":"2024-07-05","current":22.365126,"twenty":-73.07826,"median":25.015338,"eighty":29.519581,"marketCap":12639040},{"date":"2024-07-12","current":23.313894,"twenty":-71.810291,"median":24.273321,"eighty":28.980357,"marketCap":13183616},{"date":"2024-07-19","current":21.771249,"twenty":-70.527871,"median":24.005484,"eighty":28.783514,"marketCap":12305792},{"date":"2024-07-26","current":19.871565,"twenty":-67.981499,"median":23.548157,"eighty":28.579978,"marketCap":11236980},{"date":"2024-08-02","current":17.380948,"twenty":-63.611082,"median":23.313894,"eighty":28.402846,"marketCap":9828784},{"date":"2024-08-09","current":14.824233,"twenty":14.824233,"median":22.666232,"eighty":28.339976,"marketCap":8393176},{"date":"2024-08-16","current":14.891311,"twenty":14.824233,"median":22.428658,"eighty":26.393551,"marketCap":8432800},{"date":"2024-08-23","current":16.505019,"twenty":14.824233,"median":21.843651,"eighty":26.38192,"marketCap":9347200},{"date":"2024-08-30","current":15.221442,"twenty":14.891311,"median":21.615595,"eighty":26.235018,"marketCap":8617712},{"date":"2024-09-06","current":14.786956,"twenty":14.816778,"median":21.03365,"eighty":26.21652,"marketCap":8375904},{"date":"2024-09-13","current":18.291286,"twenty":14.783803,"median":19.997266,"eighty":26.012425,"marketCap":10355072},{"date":"2024-09-20","current":25.287335,"twenty":14.816778,"median":19.871565,"eighty":26.012425,"marketCap":14325600},{"date":"2024-09-27","current":18.961375,"twenty":14.877895,"median":19.084343,"eighty":25.954106,"marketCap":10769600},{"date":"2024-10-04","current":21.913118,"twenty":15.042266,"median":20.067523,"eighty":26.126798,"marketCap":12454128},{"date":"2024-10-11","current":22.176748,"twenty":15.165199,"median":20.049509,"eighty":25.99115,"marketCap":12598400},{"date":"2024-10-18","current":32.898839,"twenty":15.206634,"median":20.803771,"eighty":26.126798,"marketCap":18694400},{"date":"2024-10-25","current":23.358148,"twenty":15.219487,"median":21.352319,"eighty":26.21652,"marketCap":13270992},{"date":"2024-11-01","current":27.487373,"twenty":15.232907,"median":21.771249,"eighty":26.583872,"marketCap":15603728},{"date":"2024-11-08","current":26.826792,"twenty":15.38624,"median":21.882165,"eighty":26.827702,"marketCap":15231872},{"date":"2024-11-15","current":22.217928,"twenty":15.464941,"median":22.207911,"eighty":26.517352,"marketCap":12598400},{"date":"2024-11-22","current":19.532206,"twenty":15.526206,"median":22.192329,"eighty":26.402839,"marketCap":11076432},{"date":"2024-11-29","current":19.712189,"twenty":15.580772,"median":21.882165,"eighty":26.386572,"marketCap":11184128},{"date":"2024-12-06","current":18.691913,"twenty":15.639248,"median":21.771249,"eighty":26.293779,"marketCap":10607040},{"date":"2024-12-13","current":18.611126,"twenty":15.691094,"median":21.352319,"eighty":26.221145,"marketCap":10566400},{"date":"2024-12-20","current":7.102414,"twenty":15.639248,"median":20.803771,"eighty":26.151136,"marketCap":10058400},{"date":"2024-12-27","current":7.471029,"twenty":15.444399,"median":20.742686,"eighty":26.108587,"marketCap":10592816},{"date":"2025-01-03","current":10.196837,"twenty":15.213623,"median":20.067523,"eighty":26.07693,"marketCap":14427200},{"date":"2025-01-10","current":10.034934,"twenty":14.891311,"median":20.043836,"eighty":25.962557,"marketCap":14183360},{"date":"2025-01-17","current":9.907617,"twenty":14.749465,"median":19.895277,"eighty":25.951993,"marketCap":14008608},{"date":"2025-01-24","current":9.563114,"twenty":13.631492,"median":19.697706,"eighty":25.85141,"marketCap":13512800},{"date":"2025-01-31","current":8.48834,"twenty":10.018271,"median":19.532206,"eighty":25.746589,"marketCap":11988800},{"date":"2025-02-07","current":7.730432,"twenty":9.882149,"median":19.361654,"eighty":25.46422,"marketCap":10919968},{"date":"2025-02-14","current":7.130829,"twenty":9.483748,"median":19.090069,"eighty":25.309589,"marketCap":10081768},{"date":"2025-02-21","current":7.314786,"twenty":8.865676,"median":18.969464,"eighty":25.26403,"marketCap":10361168},{"date":"2025-02-28","current":5.889209,"twenty":8.594149,"median":18.858804,"eighty":25.21486,"marketCap":8333232},{"date":"2025-03-07","current":6.028973,"twenty":8.100004,"median":18.691913,"eighty":25.173677,"marketCap":8536432},{"date":"2025-03-14","current":5.598897,"twenty":7.846255,"median":18.496802,"eighty":25.10156,"marketCap":7926832},{"date":"2025-03-21","current":5.968988,"twenty":7.540872,"median":18.291286,"eighty":25.033931,"marketCap":8451088},{"date":"2025-03-28","current":7.03753,"twenty":7.389256,"median":18.105135,"eighty":24.856699,"marketCap":9956800},{"date":"2025-04-04","current":6.201809,"twenty":7.119463,"median":17.654152,"eighty":24.701604,"marketCap":8778240},{"date":"2025-04-11","current":6.159082,"twenty":7.009081,"median":17.557752,"eighty":24.560727,"marketCap":8737600},{"date":"2025-04-17","current":6.305413,"twenty":6.892251,"median":17.348506,"eighty":24.472151,"marketCap":8938768},{"date":"2025-04-25","current":5.299322,"twenty":6.518915,"median":16.836333,"eighty":24.40328,"marketCap":7518400},{"date":"2025-05-02","current":4.437465,"twenty":6.31653,"median":16.510738,"eighty":24.325687,"marketCap":6301232},{"date":"2025-05-09","current":5.171449,"twenty":6.285391,"median":16.156269,"eighty":24.224718,"marketCap":7317232},{"date":"2025-05-16","current":6.695699,"twenty":6.181855,"median":15.685852,"eighty":24.063819,"marketCap":6908800},{"date":"2025-05-23","current":7.021962,"twenty":6.235146,"median":15.538955,"eighty":24.008491,"marketCap":7233920},{"date":"2025-05-30","current":8.164705,"twenty":6.285272,"median":15.423857,"eighty":24.005032,"marketCap":8397532},{"date":"2025-06-06","current":8.847265,"twenty":6.289683,"median":15.216555,"eighty":23.931629,"marketCap":9092468},{"date":"2025-06-13","current":8.179292,"twenty":6.306628,"median":15.080005,"eighty":23.644242,"marketCap":8402196},{"date":"2025-06-20","current":10.670242,"twenty":6.311489,"median":14.824233,"eighty":23.64022,"marketCap":10960400}],"updateTime":1750705784164}}}